Smith & Wesson earnings missed by $0.12, revenue fell short of estimates

Smith & Wesson (SWBI) reported Q4 EPS of $0.20, missing analyst estimates of $0.32, and revenue of $140.8M, also below the consensus estimate of $153.71M. The company's stock is down -33.35% over the last 12 months, despite a 14.51% increase in the last three months, and has seen recent negative EPS revisions. InvestingPro gives Smith & Wesson a "fair performance" financial health score.

Analysis

Smith & Wesson (SWBI) reported fourth-quarter earnings per share of $0.20, a significant miss compared to the analyst consensus of $0.32, and quarterly revenue of $140.8 million, which also fell short of the $153.71 million consensus estimate. This earnings disappointment occurred despite a 14.51% increase in SWBI's stock price over the last three months, although the stock remains down -33.35% over the past twelve months. The underperformance is underscored by recent analyst sentiment, with zero positive EPS revisions and two negative EPS revisions for SWBI in the last 90 days. InvestingPro's "fair performance" financial health score for Smith & Wesson indicates a moderate fundamental standing, which is now tested by these weaker-than-expected results. The moderately negative sentiment score (-0.5 overall, -0.6 for SWBI specific) and a market impact score of 0.4 suggest an unfavorable market perception and a discernible reaction following this announcement.

Key Decisions for Investors

• Investors should anticipate potential near-term downside pressure on SWBI's stock price due to the significant Q4 earnings and revenue miss.
• The pattern of recent negative EPS revisions coupled with a "fair performance" financial health rating warrants a cautious stance on SWBI.
• Monitoring upcoming management commentary for insights into demand trends, operational challenges, and strategic responses is advisable before making new investment decisions or adjusting existing positions.